(MENAFN- GetNews)According to a new report published by Grand View Research, Growing prevalence of autoimmune diseases and increasing adoption of interleukin inhibitors are expected to drive the IL Inhibitors market growth.
The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026 , according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.
The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.
Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.
Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn’s & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).
Interleukin Inhibitors Market Report Highlights
• Psoriatic arthritis and IBD are projected to register fastest growth through to 2026
• IL-17 is likely to overtake IL-23 as the leading type by 2026
• IL-5 inhibitors for asthma to witness strong growth in the near future
• Asia Pacific is expected to exhibit the fastest regional growth.
• Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.
For Requesting a Sample Copy Please Visit @
Interleukin Inhibitors Market Segmentation
Grand View Research has segmented the global interleukin inhibitors market based on application, type, and region:
Interleukin Inhibitors Application Outlook (Revenue, USD Million, 2014 – 2026)
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Asthma
• Inflammatory Bowel Disease
• Others
Interleukin Inhibitors Type Outlook (Revenue, USD Million, 2014 – 2026)
• IL-1
• IL-5
• IL-6
• IL-17
• IL-23
• Others
Interleukin InhibitorsRegional Outlook (Revenue, USD Million, 2014 – 2026)
• North America
• The U.S.
• Canada
• Europe
• Germany
• The U.K.
• Spain
• Italy
• France
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• Saudi Arabia
• South Africa
Fill the Pre-Order Enquiry Form for the Report @
Browse Related Reports:
Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel, Remicade, Simponi, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2019 – 2026.
Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors), By Region, And Segment Forecasts, 2019 – 2025.
About Grand View Research
Grand View Research is a U.S. & India-based market research and consultancy firm. It is headquartered in San Francisco. We provide business insights, syndicated research reports, and customized research reports to large as well as small and medium-scale enterprises. Our database features thousands of statistics and in-depth analyses on more than 45 industries. Grand View Research’s extensive database is used by Fortune 500 companies to understand the regional as well as the global business environment.
MENAFN21072021003238003268ID1102487997
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.